Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did not cease developing new treatments this year. The US Food and Drug Administration maintained a rapid rate of new drug approvals this year, all while managing the urgent examination of COVID-19 tests, treatments, and vaccines under development. The FDA authorized a number of novel drugs that address previously unmet medical needs or dramatically improve patient quality of life. In 2021, 50 novel molecular entities (NMEs) received FDA approval, out of which 23 were approved in the second half. On this note, let’s take a look at major drugs launched in the second half of 2021 (H2).&n...
